Related Experiment Videos
Chronic liver disease and hepatitis-B antigen: a prospective study
Insights
Hepatitis-B antigen (HBAg) presence in chronic liver disease did not alter clinical course or outcomes. HBAg-positive chronic liver disease is not a distinct entity, and antigen clearance may signal recovery.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Chronic hepatitis and cirrhosis are significant liver conditions.
- Hepatitis-B antigen (HBAg) is a key marker in Hepatitis B virus infections.
- Understanding the clinical significance of HBAg in chronic liver disease is crucial.
Purpose of the Study:
- To investigate the long-term clinical course of patients with chronic hepatitis and cirrhosis.
- To determine if the presence of Hepatitis-B antigen (HBAg) defines a distinct clinical entity.
- To explore the relationship between HBAg, autoantibodies, and disease progression.
Main Methods:
- Long-term follow-up of 45 patients with chronic hepatitis and 41 with cirrhosis.
- Assessment of clinical, biochemical, and histological findings.
- Testing for the presence of Hepatitis-B antigen (HBAg) and autoantibodies.
Main Results:
- HBAg was detected in 42% of chronic hepatitis patients and 49% of cirrhosis patients.
- Clinical, biochemical, and histological findings were similar between HBAg-positive and HBAg-negative groups.
- Antigen persistence was observed for months to years; antigen disappearance correlated with potential disease resolution in the absence of irreversible lesions.
Conclusions:
- Hepatitis-B antigen-positive chronic liver disease does not appear to be a distinct clinical entity.
- The presence of HBAg and autoantibodies are not mutually exclusive.
- Disappearance of HBAg may indicate favorable prognosis for liver disease resolution if irreversible damage has not occurred.
Abstract:
A long-term follow-up of 45 patients with chronic hepatitis and 41 with cirrhosis is reported. Hepatitis-B antigen (HBAg) was present in 19 (42%) of the chronic hepatitis patients and in 20 (49%) of those with cirrhosis. The clinical course and biochemical and histological findings in the HBAg-positive and the HBAg-negative cases were similar, suggesting that HBAg-positive chronic liver disease is not a distinct clinical entity. The presence of antigen and autoantibodies was not found to be mutually exclusive. In HBAg-positive cases antigen tended to persist for months and years. When no irreversible lesions exist disappearance of the antigen may be a sign that the liver disease will resolve.